查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年人類微生物組市場預測：按產品、疾病、類型、應用和地區進行的全球分析
市場調查報告書
商品編碼
1383331

2030 年人類微生物組市場預測：按產品、疾病、類型、應用和地區進行的全球分析

Human Microbiome Market Forecasts to 2030 - Global Analysis By Product (Medical Foods, Prebiotics, Probiotics, Symboitics and Other Products), Disease, Type, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球人類微生物組市場規模將達到 8 億美元，預計到 2030 年將達到 63 億美元，預測期內年複合成長率為 34.1%。

「人類微生物組市場」一詞定義了專注於人類微生物組的徹底研究、分析和商業性應用的生物技術和醫療領域。它由研究、診斷、治療和個人化醫療等各個領域組成，旨在了解人體與其棲息的微生物之間的共生相互作用。

根據美國癌症協會估計，2022 年美國將報告約 1,918,030 例新癌症病例。此外，根據Globocan 2020統計，新增癌症病例數為274,364例，預計2040年將達到400,564例。

微生物組研究進展

過去幾十年來，微生物組研究取得了重大進展，使我們對微生物組與人類健康和疾病的關係的理解發生了重大變化。此外，由於高通量序列測定方法和強大的生物資訊工具，現在可以對人體內存在的大量微生物群落進行徹底分析和表徵。

法規牆

主要問題之一是微生物產品和治療方法缺乏透明和統一的法規流程。基於微生物的產品和治療方法缺乏簡單而統一的法律規範可能會限制市場擴張並增加進入障礙。然而，微生物群落的多樣性和人類微生物組的動態性質在評估產品安全性和功效時給法規機構帶來了挑戰。

慢性病盛行率呈上升趨勢

肥胖、糖尿病、發炎性腸道疾病疾病和自體免疫疾病等慢性疾病在世界各地變得越來越普遍。因此，醫學相關人員和學者正在探索以微生物為基礎的療法，以便更好地了解和管理這些慢性疾病。此外，許多發育技術都涉及恢復慢性病患者的微生物平衡，包括益生菌、糞便微生物移植 (FMT) 和微生物組控制。

研究開發費用

微生物組研究領域需要在研發 (R&D) 方面進行大量投資，以充分了解人類微生物組的複雜性並開發基於此的產品和排除項。益生菌和益生元等微生物治療方法的開發、資料分析、臨床試驗和微生物組定序都包含在這些支出中。然而，可用產品和治療方法的多樣性受到高昂的研發成本的阻礙，這可能會阻止小型企業和新興企業進入市場。

COVID-19 的影響：

全球範圍內的臨床試驗研究因 COVID-19 大流行而受到嚴重干擾。鑑於研究通常包括貧困階級，他們最容易接觸到 COVID-19，這一點尤其重要。同樣，COVID-19 已經並可能對其他公司的營運產生負面影響，包括微生物藥物和診斷設備的臨床前研究和臨床試驗。

預計益生菌產業在預測期內將是最大的

預計益生菌產業在預測期內將達到最高水準。益生菌是活的微生物，當以足夠的比例給藥宿主時，可以透過恢復或維持腸道菌叢來改善或維持宿主的整體健康。由於它能夠促進免疫健康、幫助消化和影響一般健康的許多組成部分，因此它變得非常受歡迎。此外，隨著人們越來越重視預防性健康和保健，隨著客戶尋求針對醫療問題的微生物友善治療方法，益生菌產業預計將會成長。

預計診斷領域在預測期內將呈現最高的年複合成長率。

隨著人們越來越認知到人類微生物組在健康和疾病中發揮的重要作用，診斷領域預計將在預測期內呈現最高成長率。由於定序技術和生物資訊學的進步，微生物組診斷可以更深入地了解人體微生物種群，從而實現個體化和精確的治療。此外，微生物組診斷由於其在支持疾病早期檢測、指導個體化治療策略和評估干涉措施成功與否方面的潛力而在醫療保健領域變得越來越普及。

比最大的地區

北美地區佔最大佔有率，原因在於其完善的醫療設施網路、大公司加大對開發更先進技術的投資以及加速新藥開發進程。這一領域正變得更加活躍。此外，人類微生物組治療正在引起人們的關注，與文明病變得越來越普遍，人類微生物組的次世代定序和技術進步正在取得進展。所有這些因素都促進了該地區的市場成長。

複合年複合成長率最高的地區：

由於消費者對益生菌、益生元和微生物組相關產品的興趣不斷增加，預計亞太地區將實現盈利成長。這是因為微生物組在消化、營養健康和整體健康方面的重要性正在廣泛認可。此外，亞太地區微生物組科學領域的研發活動正在增加，特別是在中國、日本和韓國等大力投資生物技術和生命科學的國家。

2022年5月，一家開發針對癌症、氣喘、自閉症和關節炎等自體免疫疾病等疾病的生物治療產品的全球製藥公司4D Pharma宣布，4D Pharma是一家針對癌症等疾病開發生物治療產品的全球製藥公司、氣喘、自閉症和關節炎等自體免疫疾病宣布，針對癌症、氣喘、自閉症和關節炎等自體自體免疫疾病等疾病開發生物治療產品的全球製藥公司4D Pharma宣布宣布開展MRx0518的臨床試驗與 PD-L1 阻斷抗體 Babencio 合併使用。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球人類微生物組市場：依產品

  • 介紹
  • 醫療食品
  • 益生元
  • 益生菌
  • 共生學
  • 其他產品

第6章 全球人類微生物組市場：依疾病分類

  • 介紹
  • 代謝
  • 內分泌
  • 傳染性的

第7章 全球人類微生物組市場：依類型

  • 介紹
  • 癌症
  • 代謝和胃腸道疾病
  • 自體免疫疾病
  • 肥胖
  • 其他類型

第8章 全球人類微生物組市場：依應用分類

  • 介紹
  • 診斷
  • 治療
  • 其他用途

第9章 全球人類微生物組市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Seres Therapeutics
  • Second Genome Inc.
  • Osel Inc.
  • Exeliom Biosciences SAS
  • Ginkgo Bioworks
  • Finch Therapeutics Group Inc.
  • Evelo Biosciences Inc
  • DuPont
  • Axial Biotherapeutics, Inc.
  • Astarte Medical
Product Code: SMRC24181

According to Stratistics MRC, the Global Human Microbiome Market is accounted for $0.8 billion in 2023 and is expected to reach $6.3 billion by 2030 growing at a CAGR of 34.1% during the forecast period. The term "Human Microbiomes Market" defines the area of biotechnology and healthcare that focuses on the thorough study, analysis, and commercial applications of the human microbiome, which is the enormous and diverse community of microorganisms that exists both inside and outside the human body. To comprehend the symbiotic interaction between the human body and its resident microorganisms, it comprises a variety of fields, including research, diagnostics, treatments, and customized medicine.

According to the American Cancer Society, 2022 estimates, there are about 1,918,030 new cases of cancer will be reported in the United States in 2022. Additionally, according to the Globocan 2020 statistics, there are 274,364 new cases of cancer and is expected to reach 400,564 new cases by 2040.

Market Dynamics:

Driver:

Research advances in the microbiome

An enormous shift has occurred in the comprehension of the human microbiome's involvement in human health and disease as a result of the substantial advancements made in the investigation of it over the past few decades. Additionally, the tremendous community of microorganisms that reside inside the human body has been thoroughly analyzed and characterized because of high-throughput sequencing methods and powerful bioinformatics tools.

Restraint:

Regulatory barriers

The lack of transparent and uniform regulatory processes for microbiome-based products and treatments is one of the main problems. The absence of simple and uniform regulatory frameworks for microbiome-based products and treatments may limit market expansion and increase entry hurdles. However, the variety of microbial communities and the dynamic nature of the human microbiome present difficulties for regulatory authorities when evaluating products' safety and efficacy.

Opportunity:

Chronic disease prevalence is on the rise

Globally, chronic illnesses such as obesity, diabetes, inflammatory bowel diseases, and autoimmune disorders are becoming more prevalent. As a result, in order to better understand and manage these chronic diseases, medical professionals and academics are exploring microbiome-based therapies. Additionally, the restoration of microbial equilibrium among individuals with chronic illnesses involves a number of developing methods, including probiotics, fecal microbiota transplantation (FMT), and microbiome regulation.

Threat:

Research and development expenses

In order to fully comprehend the complexity of the human microbiome as well as develop products and eliminates that are based on it, the field of microbiome research requires significant investments in research and development (R&D). The creation of microbiome therapies like probiotics and prebiotics, as well as data analysis, clinical trials, and microbiome sequencing, are all included in these expenditures. However, the variety of products and treatments available may be hampered by the high cost of R&D, which may prevent smaller businesses and startups from entering the market.

COVID-19 Impact:

Clinical trial research has been significantly hampered worldwide by the COVID-19 epidemic. Given that studies usually include poor people who are most in danger from COVID-19 exposure, this is very important. Similarly, COVID-19 has had a detrimental effect and might still have one on the operations of other companies, including their preclinical research and clinical testing of microbiome-based drugs and diagnostic instruments.

The probiotics segment is expected to be the largest during the forecast period

The segment for probiotics is anticipated to be the largest during the forecast period. Probiotics are living microorganisms that, when administered to a host in sufficient proportions, improve or maintain the host's overall health by restoring or maintaining their intestinal microbiome. Due to their significance in promoting immune health, boosting digestion, and potentially affecting a number of different elements of general wellbeing, they have grown tremendously popular. Furthermore, with an increasing emphasis on preventive health and wellness, the probiotics sector is anticipated to develop as customers look for microbiome-friendly remedies to their medical issues.

The diagnostics segment is expected to have the highest CAGR during the forecast period

Due to the growing awareness of the crucial role played by the human microbiome in health and illness, the diagnostics segment is anticipated to have the highest growth rate throughout the projection period. Microbiome diagnostics can offer a deeper comprehension of the microbial populations within the body due to developments in sequencing technologies and bioinformatics, enabling personalized and precise therapy. Moreover, microbiome diagnostics are also becoming more popular in healthcare due to their potential to support early disease detection, guide individualized treatment strategies, and assess the success of interventions.

Region with largest share:

North America held the largest share due to an established network of healthcare facilities, greater investment from major firms in developing more advanced technology, accelerating the process of creating new drugs, and a rise in research efforts in this field. Additionally, human microbiome treatments are getting more attention, lifestyle ailments are becoming more prevalent, and next-generation sequencing and the human microbiome are experiencing more technological advancements. These factors are all contributing to the market's growth in the region.

Region with highest CAGR:

Due to growing consumer interest in probiotics, prebiotics, and microbiome-focused products, the Asia-Pacific area is predicted to experience profitable growth. This is due to digestion, nutritional wellness, and the importance of the microbiome in overall well-being which are becoming more widely recognized. Additionally, the Asia Pacific area has experienced a rise in research and development activities in the field of microbiome science, especially in nations like China, Japan, and South Korea that have made significant investments in biotechnology and the life sciences.

Key players in the market

Some of the key players in Human Microbiome market include: Seres Therapeutics, Second Genome Inc., Osel Inc., Exeliom Biosciences SAS, Ginkgo Bioworks, Finch Therapeutics Group Inc., Evelo Biosciences Inc, DuPont, Axial Biotherapeutics, Inc. and Astarte Medical.

Key Developments:

In January 2023, Genetic Analysis AS, a research driven diagnostic company that focuses on innovative diagnostic solutions with microbiota analysis, entered into an agreement with Microbiome Research Pvt. Ltd., a India-based microbiome company, for launching a test service portfolio based on the GA-map Dysbiosis Test, and thus, making it the first CE-IVD marked standardized gut microbiome test.

In May 2022, 4D Pharma, a global pharmaceutical company that develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis, announced clinical trial for MRx0518 with combination bavencio, a PD - L1 blocking antibody indicated for the treatment of urothelial cancer

Products Covered:

  • Medical Foods
  • Prebiotics
  • Probiotics
  • Symboitics
  • Other Products

Diseases Covered:

  • Metabolic
  • Endocrine
  • Infectious

Types Covered:

  • Cancer
  • Metabolic and Gastrointestinal Disorders
  • Autoimmune Disorder
  • Obesity
  • Other Types

Applications Covered:

  • Diagnostics
  • Therapeutics
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Human Microbiome Market, By Product

  • 5.1 Introduction
  • 5.2 Medical Foods
  • 5.3 Prebiotics
  • 5.4 Probiotics
  • 5.5 Symboitics
  • 5.6 Other Products

6 Global Human Microbiome Market, By Disease

  • 6.1 Introduction
  • 6.2 Metabolic
  • 6.3 Endocrine
  • 6.4 Infectious

7 Global Human Microbiome Market, By Type

  • 7.1 Introduction
  • 7.2 Cancer
  • 7.3 Metabolic and Gastrointestinal Disorders
  • 7.4 Autoimmune Disorder
  • 7.5 Obesity
  • 7.6 Other Types

8 Global Human Microbiome Market, By Application

  • 8.1 Introduction
  • 8.2 Diagnostics
  • 8.3 Therapeutics
  • 8.4 Other Applications

9 Global Human Microbiome Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Seres Therapeutics
  • 11.2 Second Genome Inc.
  • 11.3 Osel Inc.
  • 11.4 Exeliom Biosciences SAS
  • 11.5 Ginkgo Bioworks
  • 11.6 Finch Therapeutics Group Inc.
  • 11.7 Evelo Biosciences Inc
  • 11.8 DuPont
  • 11.9 Axial Biotherapeutics, Inc.
  • 11.10 Astarte Medical

List of Tables

  • Table 1 Global Human Microbiome Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
  • Table 4 Global Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
  • Table 5 Global Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
  • Table 6 Global Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
  • Table 7 Global Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
  • Table 9 Global Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
  • Table 10 Global Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 11 Global Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
  • Table 12 Global Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
  • Table 13 Global Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 14 Global Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 15 Global Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
  • Table 16 Global Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 17 Global Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 18 Global Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
  • Table 19 Global Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 20 Global Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 21 Global Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 22 North America Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
  • Table 23 North America Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
  • Table 24 North America Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
  • Table 25 North America Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
  • Table 26 North America Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
  • Table 27 North America Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
  • Table 28 North America Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 29 North America Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
  • Table 30 North America Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
  • Table 31 North America Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 32 North America Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
  • Table 33 North America Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
  • Table 34 North America Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 35 North America Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 36 North America Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
  • Table 37 North America Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 38 North America Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 39 North America Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
  • Table 40 North America Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 41 North America Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 42 North America Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 43 Europe Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Europe Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
  • Table 45 Europe Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
  • Table 46 Europe Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
  • Table 47 Europe Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
  • Table 48 Europe Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
  • Table 49 Europe Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 50 Europe Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
  • Table 51 Europe Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
  • Table 52 Europe Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 53 Europe Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
  • Table 54 Europe Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
  • Table 55 Europe Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 56 Europe Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 57 Europe Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
  • Table 58 Europe Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 59 Europe Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 60 Europe Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
  • Table 61 Europe Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 62 Europe Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 63 Europe Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 64 Asia Pacific Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
  • Table 65 Asia Pacific Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
  • Table 66 Asia Pacific Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
  • Table 67 Asia Pacific Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
  • Table 68 Asia Pacific Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
  • Table 69 Asia Pacific Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
  • Table 70 Asia Pacific Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 71 Asia Pacific Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
  • Table 72 Asia Pacific Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
  • Table 73 Asia Pacific Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 74 Asia Pacific Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
  • Table 75 Asia Pacific Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
  • Table 76 Asia Pacific Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 77 Asia Pacific Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 78 Asia Pacific Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
  • Table 79 Asia Pacific Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 80 Asia Pacific Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 81 Asia Pacific Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
  • Table 82 Asia Pacific Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 83 Asia Pacific Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 84 Asia Pacific Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 85 South America Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
  • Table 86 South America Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
  • Table 87 South America Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
  • Table 88 South America Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
  • Table 89 South America Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
  • Table 90 South America Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
  • Table 91 South America Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 92 South America Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
  • Table 93 South America Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
  • Table 94 South America Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 95 South America Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
  • Table 96 South America Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
  • Table 97 South America Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 98 South America Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 99 South America Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
  • Table 100 South America Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 101 South America Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 102 South America Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
  • Table 103 South America Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 104 South America Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 105 South America Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 106 Middle East & Africa Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
  • Table 107 Middle East & Africa Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
  • Table 108 Middle East & Africa Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
  • Table 109 Middle East & Africa Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
  • Table 110 Middle East & Africa Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
  • Table 111 Middle East & Africa Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
  • Table 112 Middle East & Africa Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 113 Middle East & Africa Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
  • Table 114 Middle East & Africa Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
  • Table 115 Middle East & Africa Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 116 Middle East & Africa Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
  • Table 117 Middle East & Africa Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
  • Table 118 Middle East & Africa Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 119 Middle East & Africa Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 120 Middle East & Africa Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
  • Table 121 Middle East & Africa Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 122 Middle East & Africa Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 123 Middle East & Africa Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
  • Table 124 Middle East & Africa Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 125 Middle East & Africa Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 126 Middle East & Africa Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)